범불안장애(GAD)- 시장 인사이트, 역학, 시장 예측(2036년)

Key Highlights:

• The Generalized Anxiety Disorder treatment market is shaped by a complex interplay of drivers and barriers. On the one hand, the increasing Generalized Anxiety Disorder prevalence of anxiety disorders and a rising awareness of mental health drive market growth. Advances in pharmacological research and the development of novel therapies further fuel this expansion. Conversely, high costs of treatment, side effects associated with existing medications, and stigma around mental health present formidable barriers. Nonetheless, the Generalized Anxiety Disorder market size is poised for growth, driven by promising new treatments like MM-120 (LSD D-Tartrate), Fasedienol (PH94B), and others.
• DelveInsight's analyst projects that among the total diagnosed prevalent cases of Generalized Anxiety Disorder in 7MM, approximately 53% of cases were from the US. As per our estimations, in 2023, the EU4 and the UK accounted for nearly 6 million diagnosed prevalent cases of Generalized Anxiety Disorder.
• In the US, the Generalized Anxiety Disorder Treatment Market mainly consisted of standard treatments like SSRIs/SNRIs, Benzodiazepines, Tricyclic Antidepressants/Azapirone (Buspirone), and others (Antiepileptics, antipsychotics, etc.), which generated nearly USD 1,019 million in 2023.

DelveInsight's "Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of the GAD, historical and forecasted epidemiology and the GAD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Generalized Anxiety Disorder treatment market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Generalized Anxiety Disorder market size from 2022 to 2036. The report also covers current Generalized Anxiety Disorder treatment market practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2022-2036

Key Factors Driving the Growth of the Generalized Anxiety Disorder Market

• Rising GAD Prevalence: According to the estimates, the diagnosed prevalent cases of GAD are expected to increase during the forecast period, driven by sustained exposure to psychosocial stressors, urbanization and lifestyle changes, economic uncertainty, social isolation, comorbid chronic conditions, substance use, and population growth across key markets.
• Advances in Diagnostic Tools: Improved screening tools and standardized diagnostic criteria (like DSM-5) enable earlier and more accurate detection of GAD. Primary care settings are increasingly equipped to screen for anxiety, leading to more referrals and treatment initiations.
• Rise of Telemedicine and Digital Health: Tele-mental health services have expanded access to care, especially in underserved regions. Digital therapeutic platforms, mobile apps, and online cognitive behavioral therapy (CBT) tools enhance engagement and continuity of treatment.
• Launch of Emerging GAD Drugs: The dynamics of the GAD market are expected to change in the coming years due to the launch of emerging therapies such as DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies, Inc.), ABBV-932 (AbbVie), and others.

Generalized Anxiety Disorder Treatment Market

Generalized Anxiety Disorder is a prevalent mental health condition characterized by excessive and persistent worry, often extending beyond specific triggers. Individual's with GAD experience heightened levels of anxiety, anticipating future events and exhibiting physical symptoms such as muscle tension and restlessness. The disorder significantly impairs daily functioning and quality of life.

The Generalized Anxiety Disorder pathophysiology associated with dysregulation in neurotransmitter systems, particularly involving imbalances in serotonin, gamma-aminobutyric acid (GABA), and norepinephrine. Structural and functional alterations in brain regions such as the amygdala, prefrontal cortex, and limbic system contribute to heightened reactivity to stressors, impaired emotional regulation, and the persistent, excessive worry characteristic of Generalized Anxiety Disorder.

Generalized Anxiety Disorder Diagnosis

The diagnosis of Generalized Anxiety Disorder involves a comprehensive assessment of an individual's mental health, considering the presence of excessive and uncontrollable worry across various aspects of life for a minimum of six months. Clinicians utilize standardized psychiatric interviews and validated screening tools to evaluate the severity of anxiety symptoms, along with a thorough exploration of associated physical and psychological manifestations. Differential diagnosis is crucial to rule out other psychiatric conditions, medical disorders, or substance-related issues that may mimic GAD symptoms. The diagnostic process also entails considering the impact of anxiety on daily functioning and its persistence in the absence of identifiable stressors. A multidimensional approach aids in ensuring an accurate diagnosis and facilitates the development of an effective treatment plan tailored to the individual's needs.

Generalized Anxiety Disorder Treatment

The primary treatment goal for Generalized Anxiety Disorder is to alleviate symptoms and improve overall functioning, aiming for a reduction in excessive and uncontrollable worry. Therapeutic interventions, including psychotherapy (such as cognitive-behavioral therapy) and pharmacotherapy (commonly with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors), are employed to achieve symptom relief, enhance coping mechanisms, and improve the individual's quality of life. Additionally, treatment strategies often focus on preventing relapse and managing coexisting conditions to support long-term well-being.

Generalized Anxiety Disorder Epidemiology

As the market is derived using the patient-based model, the GAD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total 12-month Diagnosed Prevalent Cases of GAD, Gender-specific Diagnosed Prevalent Cases of GAD, Age-specific Diagnosed Prevalent Cases of GAD, and Severity-specific Diagnosed Prevalent Cases of GAD in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, from 2022 to 2036. As per DelveInsight's estimations, the total diagnosed prevalent cases of GAD in the 7MM were approximately 16 million in 2023 and are projected to increase during the forecast period.

• The overall count of individuals diagnosed with Generalized Anxiety Disorder in the United States was approximately 8,770 thousand in 2023, and these numbers are expected to increase at an estimated CAGR throughout the study period (2022-2036).
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of Generalized Anxiety Disorder, with 1,460 thousand cases, followed by Italy and Spain in 2023. On the other hand, the UK had the lowest prevalent population in the European region in 2023.
• In 2023, Japan reported approximately 1,360 thousand diagnosed prevalent cases of GAD.
• Gender-specific diagnosed prevalent cases of Generalized Anxiety Disorder showed that females were more affected by GAD than males in the 7MM.
• As per DelveInsight's analysis, the diagnosed prevalent cases of Generalized Anxiety Disorder based on age were categorized into four groups: 18-29 years, 30-44 years, 45-59 years, and 60 years and above. The highest proportion of Generalized Anxiety Disorder cases was estimated in the 45-59 years age group in the 7MM, while the least cases were in the age group 18-29 years.
• The cases of Generalized Anxiety Disorder were classified based on severity levels, into mild, moderate, and severe categories. DelveInsight's estimations reveal that the highest number of severity-specific cases in the US was attributed to moderate cases, totaling 3,910 thousand, in 2023.

Recent Developments of Generalized Anxiety Disorder Clinical Trials

• In January 2026, MindMed rebranded to Definium Therapeutics, outlining multiple anticipated Phase III milestones in GAD in 2026. The company expects topline data from two pivotal Phase III studies of DT120 ODT in GAD, with results from Voyage anticipated in the second quarter of 2026 and Panorama in the second half of 2026.
• In September 2025, Seaport Therapeutics advanced another prodrug candidate developed using its proprietary Glyph platform, GlyphAgo (SPT-320), into Phase I clinical development for GAD. GlyphAgo is a modified agomelatine designed to enhance lymphatic absorption and systemic exposure, supporting its transition from preclinical research into human studies.

Generalized Anxiety Disorder Drug Chapters

The drug chapter segment of the Generalized Anxiety Disorder treatment market report encloses a detailed analysis of marketed GAD drugs and mid-late stage (Phase III and Phase II) pipeline drugs. It also understands Generalized Anxiety Disorder clinical trials details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Generalized Anxiety Disorder Drugs

• DT120 ODT (LSD D-Tartrate): Definium Therapeutics

DT120 orally disintegrating tablet is Definium Therapeutic's optimized form of lysergide D-tartrate (LSD), designed to enhance bioavailability, enable rapid absorption, and minimize gastrointestinal side effects using Catalent's Zydis fast-dissolve technology. DT120 ODT acts as a partial agonist at serotonin receptors, increasing brain connectivity, which may help alleviate symptoms of GAD by addressing underlying neural dysregulation.

• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka

Ulotaront is an investigational trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist being developed as a novel oral treatment for GAD. By targeting these receptors, ulotaront aims to modulate neurotransmitter activity differently from traditional anxiolytics, potentially offering a new mechanism of action for managing GAD. The drug is currently undergoing Phase II/III clinical trials in both the US and Japan to evaluate its efficacy and safety in treating GAD.

Generalized Anxiety Disorder Market Outlook

Generalized Anxiety Disorder has a diverse treatment classification associated with the disease landscape. The standard array of pharmacological agents employed in the management of GAD encompasses a diverse range, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), antiepileptics like pregabalin, tricyclic antidepressants (TCAs) that impact mood regulation, benzodiazepines offering rapid relief, antihistamines, atypical antipsychotics, and antioxidants.

• The Generalized Anxiety Disorder Treatment Market is expected to experience positive growth with the approval of potential drugs like Fasedienol, MM-120, and others.
• The Generalized Anxiety Disorder market size in the 7MM reached approximately USD 1,560 million in 2023. Projections indicate a substantial growth during the forecast period.
• Out of the 7MM, the United States dominated the Generalized Anxiety Disorder Market in 2023, representing the largest Generalized Anxiety Disorder Market share at nearly 65%.
• In 2023, EU4 and the UK captured an estimated USD 472 million, which is anticipated to increase at a substantial CAGR. Among the European countries, Germany covered the largest Generalized Anxiety Disorder market share in 2023, followed by Italy, and Spain.
• Japan alone represented approximately 5% of the total Generalized Anxiety Disorder Market in 2023, projected to increase at a substantial CAGR during the study period.

Generalized Anxiety Disorder Drugs Uptake

This section focuses on the uptake rate of potential Generalized Anxiety Disorder drugs expected to launch in the market during 2024-2034. For example, Fasedienol (PH94B) in the US is expected to be launched by 2028 with a peak share of 6%. It is expected to take 7 years to peak with a medium uptake.

Generalized Anxiety Disorder Pipeline Development Activities

The Generalized Anxiety Disorder therapeutics market report provides insights into different Generalized Anxiety Disorder clinical trials within Phase III, Phase II, and Phase I stage. It also analyzes key Generalized Anxiety Disorder Companies involved in developing targeted therapeutics.

Pipeline Development Activities

The Generalized Anxiety Disorder therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging Generalized Anxiety Disorder therapies.

KOL Views on Generalized Anxiety Disorder

To keep up with current Generalized Anxiety Disorder market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on GAD evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Charite - Universitatsmedizin Berlin; Klinik fur Psychiatrie und Psychotherapie - Universitatsklinikum Heidelberg, Pitie-Salpetriere Hospital, Paris, Groupe Hospitalier Paris Saint-Joseph, Tokyo Medical University Hospital, Keio University Hospital, Tokyo, Osaka University Hospital, and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or GAD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging Generalized Anxiety Disorder therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Generalized Aniety Disorder Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment. The Generalized Anxiety Disorder therapeutics market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Generalized Anxiety Disorder Market Report Scope

• The Generalized Anxiety Disorder treatment market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Generalized Anxiety Disorder treatment market landscape.
• A detailed review of the Generalized Anxiety Disorder drugs market, historical and forecasted Generalized Anxiety Disorder market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The Generalized Anxiety Disorder therapeutics market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Generalized Anxiety Disorder Drugs Market.

Generalized Anxiety Disorder Therapeutics Market Report Insights

• Patient-based Generalized Anxiety Disorder Market Forecasting
• Generalized Anxiety Disorder Therapeutic Approaches
• Generalized Anxiety Disorder Pipeline Analysis
• Generalized Anxiety Disorder Market Size and Trends
• Existing and Future Generalized Anxiety Disorder Drugs Market Opportunity

Generalized Anxiety Disorder Market Report Key Strengths

• 11 years Generalized Anxiety Disorder Market Forecast
• The 7MM Coverage
• Generalized Anxiety Disorder Epidemiology Segmentation
• Key Cross Competition
• Attribute Analysis
• Generalized Anxiety Disorder Drugs Uptake
• Key Generalized Anxiety Disorder Market Forecast Assumptions

Generalized Anxiety Disorder Market Report Assessment

• Current Generalized Anxiety Disorder Treatment Market Practices
• Generalized Anxiety Disorder Unmet Needs
• Generalized Anxiety Disorder Pipeline Product Profiles
• Generalized Anxiety Disorder Therapeutics Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Generalized Anxiety Disorder Market Drivers
• Generalized Anxiety Disorder Market Barriers

Key Questions:

Generalized Anxiety Disorder Market Insights

• What was the Generalized Anxiety Disorder market size, the Generalized Anxiety Disorder treatment market size by therapies, and Generalized Anxiety Disorder market share (%) distribution in 2022, and how would it all look in 2036? What are the contributing factors for this growth?
• What unmet needs are associated with the current Generalized Anxiety Disorder treatment market?
• What are the patents of emerging therapies for Generalized Anxiety Disorder?
• Which Generalized Anxiety Disorder drug is going to be the largest contributor by 2036?
• What are the pricing variations among different geographies for approved and off-label Generalized Anxiety Disorder therapies?
• How would the market drivers, barriers, and future opportunities affect the Generalized Anxiety Disorder market dynamics and subsequent analysis of the associated trends?

Generalized Anxiety Disorder Epidemiology Insights

• What are the disease risks, burdens, and Generalized Anxiety Disorder Unmet Needs? What will be the growth opportunities across the 7MM concerning the patient population of Generalized Anxiety Disorder?
• What is the historical and forecasted Generalized Anxiety Disorder patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for GAD and why?
• What factors are affecting the diagnosis of the indication?

Current Generalized Anxiety Disorder Treatment Market Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for treating Generalized Anxiety Disorder? What are the current guidelines for treating Generalized Anxiety Disorder in the US and Europe?
• How many companies are developing therapies for treating Generalized Anxiety Disorder?
• How many emerging Generalized Anxiety Disorder therapies are in the mid-stage and late stage of development for treating GAD?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the key designations that have been granted for the emerging therapies for GAD?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted Generalized Anxiety Disorder market?

Reasons to Buy:

• The Generalized Anxiety Disorder treatment market report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Generalized Anxiety Disorder Drugs Market.
• Insights on patient burden/ Generalized Anxiety Disorder prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing Generalized Anxiety Disorder market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Generalized Anxiety Disorder drugs market will help devise strategies that will help get ahead of competitors.
• Detailed analysis and ranking of potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Generalized Anxiety Disorder drugs market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1 Key Insights

2 Report Introduction

3 GAD Market Overview at a Glance

• 3.1 Market Share (%) Distribution by Therapies of GAD in 2022
• 3.2 Market Share (%) Distribution by Therapies of GAD in 2036

4 Epidemiology and Market Methodology of GAD

5 Executive Summary of GAD

6 Key Events

7 Disease Background and Overview

• 7.1 Introduction
• 7.2 Causes and Risk Factors
• 7.3 Signs and Symptoms
• 7.4 Pathophysiology
• 7.5 Diagnosis
  • 7.5.1 Diagnostic Algorithm
  • 7.5.2 Screening Tools
• 7.6 Treatment and Management of Generalized Anxiety Disorder
  • 7.6.1 Treatment of special populations
  • 7.6.2 Treatment Algorithm
  • 7.6.3 Treatment Guidelines
    • 7.6.3.1 Recommendations as per American Family Physician
    • 7.6.3.2 National Institute for Health and Care Excellence (NICE):GAD Management
    • 7.6.3.3 Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical Practice Guideline for Social Anxiety Disorder (2021)
  • 7.6.4 Treatment Recommendation Summary

8 Epidemiology and Patient Population

• 8.1 Key Findings
• 8.2 Assumptions and Rationale of GAD
  • 8.2.1 The United States
  • 8.2.2 EU4 and the UK
  • 8.2.3 Japan
• 8.3 Total Diagnosed Prevalent Cases of GAD in the 7MM
• 8.4 The United States
  • 8.4.1 Total Diagnosed Prevalent Cases of GAD in the US
  • 8.4.2 Gender-specific Diagnosed Prevalent Cases of GAD in the US
  • 8.4.3 Age-specific Diagnosed Prevalent Cases of GAD in the US
  • 8.4.4 Severity-specific Diagnosed Prevalent Cases of GAD in the US
• 8.5 EU4 and the UK
  • 8.5.1 Germany
    • 8.5.1.1 Total Diagnosed Prevalent Cases of GAD in Germany
    • 8.5.1.2 Gender-specific Diagnosed Prevalent Cases of GAD in Germany
    • 8.5.1.3 Age-specific Diagnosed Prevalent Cases of GAD in Germany
    • 8.5.1.4 Severity-specific Diagnosed Prevalent Cases of GAD in Germany
  • 8.5.2 France
    • 8.5.2.1 Total Diagnosed Prevalent Cases of GAD in France
    • 8.5.2.2 Gender-specific Diagnosed Prevalent Cases of GAD in France
    • 8.5.2.3 Age-specific Diagnosed Prevalent Cases of GAD in France
    • 8.5.2.4 Severity-specific Diagnosed Prevalent Cases of GAD in France
  • 8.5.3 Italy
    • 8.5.3.1 Total Diagnosed Prevalent Cases of GAD in Italy
    • 8.5.3.2 Gender-specific Diagnosed Prevalent Cases of GAD in Italy
    • 8.5.3.3 Age-specific Diagnosed Prevalent Cases of GAD in Italy
    • 8.5.3.4 Severity-specific Diagnosed Prevalent Cases of GAD in Italy
  • 8.5.4 Spain
    • 8.5.4.1 Total Diagnosed Prevalent Cases of GAD in Spain
    • 8.5.4.2 Gender-specific Diagnosed Prevalent Cases of GAD in Spain
    • 8.5.4.3 Age-specific Diagnosed Prevalent Cases of GAD in Spain
    • 8.5.4.4 Severity-specific Diagnosed Prevalent Cases of GAD in Spain
  • 8.5.5 The UK
    • 8.5.5.1 Total Diagnosed Prevalent Cases of GAD in the UK
    • 8.5.5.2 Gender-specific Diagnosed Prevalent Cases of GAD in the UK
    • 8.5.5.3 Age-specific Diagnosed Prevalent Cases of GAD in the UK
    • 8.5.5.4 Severity-specific Diagnosed Prevalent Cases of GAD in the UK
• 8.6 Japan
  • 8.6.1 Total Diagnosed Prevalent Cases of GAD in Japan
  • 8.6.2 Gender-specific Diagnosed Prevalent Cases of GAD in Japan
  • 8.6.3 Age-specific Diagnosed Prevalent Cases of GAD in Japan
  • 8.6.4 Severity-specific Diagnosed Prevalent Cases of GAD in Japan

9 Patient Journey

10 Emerging Therapies

• 10.1 Key Cross Competition
• 10.2 Fasedienol (PH94B): VistaGen Therapeutics
  • 10.2.1 Product Description
  • 10.2.2 Other Development Activities
  • 10.2.3 Clinical Trials Information
  • 10.2.4 Safety and Efficacy
  • 10.2.5 Analysts' Views
• 10.3 MM-120: MindMed
  • 10.3.1 Product Description
  • 10.3.2 Other Development Activities
  • 10.3.3 Clinical Trials Information
  • 10.3.4 Safety and Efficacy
  • 10.3.5 Analysts' Views
• 10.4 CYB004: Cybin IRL Limited
  • 10.4.1 Product Description
  • 10.4.2 Other Development Activities
  • 10.4.3 Clinical Trials Information
  • 10.4.4 Safety and Efficacy
  • 10.4.5 Analysts' Views

11 GAD: Market Analysis

• 11.1 Key Findings
• 11.2 Key Market Forecast Assumptions
• 11.3 Market Outlook
• 11.4 Total Market Size of GAD in the 7MM
• 11.5 Market Size of GAD by Therapies in the 7MM
• 11.6 Market Size of GAD in the United States
  • 11.6.1 Total Market Size of GAD
  • 11.6.2 Market Size of GAD by Therapies in the United States
• 11.7 Market Size of GAD in EU4 and the UK
  • 11.7.1 Germany
    • 11.7.1.1 Total Market Size of GAD
    • 11.7.1.2 Market Size of GAD by Therapies in Germany
  • 11.7.2 France
    • 11.7.2.1 Total Market Size of GAD
    • 11.7.2.2 Market Size of GAD by Therapies in France
  • 11.7.3 Italy
    • 11.7.3.1 Total Market Size of GAD
    • 11.7.3.2 Market Size of GAD by Therapies in Italy
  • 11.7.4 Spain
    • 11.7.4.1 Total Market Size of GAD
    • 11.7.4.2 Market Size of GAD by Therapies in Spain
  • 11.7.5 The UK
    • 11.7.5.1 Total Market Size of GAD
    • 11.7.5.2 Market Size of GAD by Therapies in the UK
• 11.8 Market Size of GAD in Japan
  • 11.8.1 Total Market Size of GAD
  • 11.8.2 Market Size of GAD by Therapies in Japan

12 Key Opinion Leaders' Views

13 SWOT Analysis

14 Unmet Needs

15 Market Access and Reimbursement

• 15.1 The United States
  • 15.1.1 Center for Medicare and Medicaid Services (CMS)
• 15.2 In EU4 and the UK
  • 15.2.1 Germany
  • 15.2.2 France
  • 15.2.3 Italy
  • 15.2.4 Spain
  • 15.2.5 The United Kingdom
• 15.3 Japan
  • 15.3.1 MHLW

16 Appendix

• 16.1 Bibliography
• 16.2 Acronyms and Abbreviations
• 16.3 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer